glioblastoma – MJ Shareholders https://mjshareholders.com The Ultimate Marijuana Business Directory Fri, 30 Jul 2021 12:40:00 +0000 en-US hourly 1 https://wordpress.org/?v=6.5.3 New CBD Trials Point the Way for Enveric, MagicMed https://mjshareholders.com/new-cbd-trials-point-the-way-for-enveric-magicmed/ Fri, 30 Jul 2021 12:40:00 +0000 https://www.cannabisfn.com/?p=2927827

Ryan Allway

July 30th, 2021

Psychedelics, Top Story

As the cannabis industry strives to gain widespread acceptance in the mainstream, scientific studies into the potential benefits of the plant and its active ingredients play a key role in reaching that goal. There are currently very few approved pharmaceutical drug applications for cannabinoids, but that could change. After decades of effective prohibition there is a growing body of research surrounding cannabinoids, and more drug approvals are likely to follow.

All of the above applies equally to the promising area of psychedelic research, though the psychedelic industry is at an even earlier stage than the cannabis industry. Studies point to potential benefits for patients suffering from conditions such as PTSD, anxiety, addiction, and depression to name a few. More research is needed and getting psychedelics into clinical trials is really the next step.

Two companies on the verge of a merger are looking to push clinical research forward in both areas. Enveric Biosciences (NASDAQ: ENVB) is a pioneer in cannabinoid research that recently announced a Phase 1/2 trial focused on CBD as a complementary treatment for recurrent cases of the devastating brain cancer glioblastoma (GBM). Enveric also recently announced a definitive agreement to acquire and combine with MagicMed Industries, a leader in the research and development of novel derivative psychedelic molecules designed for clinical use. The combination of the two companies has the potential to greatly advance pharmaceutical development in both sectors.

Clinical Trial

Enveric’s clinical trial has been approved by the Israeli Ministry of Health and will be conducted at the Davidoff Institute of Oncology, Rabin Medical Center, in Israel under Principal Investigator Dr. Tali Siegal. Israel has long been a global leader in cannabis research with the backing of the federal government, and the country continues to push the boundaries of our knowledge of the plant and its benefits.

GBM is the most common and lethal form of cancer affecting the central nervous system. Five year survival rates for patients with the disease are very poor, with about 5% surviving through that time and the average length of survival less than two years. Despite much research over the last few decades, these rates remain largely unchanged.

Enveric is studying the combination of its lead synthetic CBD candidate, EV101, with two currently accepted forms of treatment for GBM. Preclinical data supports the idea of the combined treatments, which suggest that CBD may improve the efficacy of chemo- or immuno-therapies while potentially allowing for lower doses of chemotherapeutic agents.

Glioblastoma tumors express CB2 receptors, which are the channels through which CBD and other cannabinoids are thought to exert their anti-cancer effects. Research indicates CBD may induce apoptosis, or cell death, in cancer cells. The results of Enveric’s Phase 1/2 trial could greatly further the understanding of these mechanisms and ideally improve outcomes for GBM patients.

The Combined Company

MagicMed has established a growing library, called the Psybrary™, of novel compounds based on or derived from psychedelic molecules such as psilocybin and DMT. The company’s approach is to create patentable drug candidates that enhance the therapeutic effects of the naturally occurring molecules. MagicMed’s expertise lies in research and development, and its business model is to sell or license these drug candidates to pharmaceutical companies, like Enveric, with the capabilities to conduct clinical trials.

With the pending acquisition, the combined companies would be able to keep the whole process, from drug discovery and molecule development through clinical trials and drug approval, under one roof. The hope is to advance psychedelic therapies and research into the mainstream and, of course, gain approvals for drug treatments of major indications like anxiety, PTSD, and depression. The fact that Enveric is listed on the NASDAQ and has clinical trial experience should only work to the benefit of achieving those goals, both in terms of access to capital for development and more generally the acceptance of psychedelic research in the investment community.

Once the deal is finalized, some members of the MagicMed executive team will assume their existing roles in the new version of Enveric Biosciences. CEO Dr. Joseph Tucker will become CEO of Enveric, with current Enveric CEO David Johnson becoming the Executive Chairman. Meanwhile, MagicMed CSO Dr. Peter Facchini and CTO Dr. Jillian Hagel will be named to the same positions in the new company.

The Takeaway

Investors interested in early mover companies in emerging health care sectors may want to track Enveric Biosciences’ development. Upcoming inflection points include the GBM trial, the finalization of the merger between MagicMed and Enveric, and the further development of potential psychedelic therapies. The combined capabilities of the two companies could serve to greatly enhance our understanding of both cannabis and psychedelic science after decades of neglect. Stay tuned.

Disclaimer

The above article is sponsored content. CannabisFN.com and CFN Media, have been hired to create awareness. Please follow the link below to view our full disclosure outlining our compensation: http://www.cannabisfn.com/legal-disclaimer/

This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.

About Ryan Allway

Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.

]]> Gabriella’s Kitchen Is Redefining The Cannabis Health and Wellness Industry https://mjshareholders.com/gabriellas-kitchen-is-redefining-the-cannabis-health-and-wellness-industry/ Mon, 12 Nov 2018 13:30:22 +0000 http://www.cannabisfn.com/?p=1876379

Ryan Allway

November 12th, 2018

News, Top Story

Gabriella’s Kitchen (CSE: GABY), the award-winning consumer packaged goods company whose array of super-nutritional foods are currently sold in more than 3,400 stores across North America, is launching a revolutionary new line of cannabis infused nutritional edibles. The expansion as well as a number of announced acquisitions has positioned the company on the cutting edge of cannabis infused nutritional edibles and therapeutic products, further accelerating GABY’s mission, “to empower people to live healthy lives without compromise.”  

Passionate Mission

GABY, founded by sisters Gabriella and Margot Micallef, was inspired by Gabriella’s terminal cancer diagnosis. Though Gabriella ultimately passed away from her illness, she beat her 4 month prognosis by an exponential factor of 10 and enjoyed a much higher quality of life than her doctors predicted. According to Margot Micallef, Founder & CEO of GABY, “The experience of Gabriella’s journey with cancer confirmed our views that diet and lifestyle is a real alternative to pharma and often with better results!”

GABY’s passionate mission has been furthered by the launch of its cannabis infused edibles  which are now in market in California under the alto™ brand. Uninfused versions of the same alto™ edibles are also available online at www.Gabriellas-kitchen.com. In addition, GABY has another 20 uninfused products in market in California and throughout the US and Canada in thousands of mainstream retailers, creating a fast-track to the mainstream retail market for its soon to be launched Hemp-CBD infused edibles.

Expansion Into Cannabis Infused Edibles & Wellness Products

Given the importance of California as both a cannabis and a wellness market, GABY determined it was crucial to own its infrastructure in California. Therefore, in September, Gabriella’s Kitchen acquired The Oil Plant, Inc. (TOP), the owner of a Type 6 manufacturing license issued by the California Bureau of Cannabis Control (CBCC). In October, GABY announced the acquisition of Sonoma Pacific Distribution, one of California’s leading independently owned cannabis distribution and marketing companies with a distribution and transport license issued by CBCC. With these acquisitions and with GABY’s vast and deep retail and consumer packaged goods experience, GABY has one of the most reliable and fastest go to market strategies of any cannabis company trading today. Uniquely, while others rely on third party relationships, GABY has the advantage of having direct control over the development, manufacturing, distribution and sale of its cannabis products in the world’s most important market.  

Through these acquisitions GABY also acquired the benefit of TOP’s best in class cannabis oil extraction technology and TOP’s interest in the market-leading brand of Aunt Zelda’s™ topicals and tinctures. The products are featured in the film Weed the People – a documentary by the renowned film production team of Abby Epstein and Ricki Lake.   

Cannabinoids are unique organic compounds commonly found in the cannabis plant. In multiple studies, both cannabidiol (CBD) and tetrahydrocannabinol (THC) have proven to have powerful wellness properties, including pain relief, inflammation relief, sleep enhancements, and general wellness. The combination of GABY’s move into CBD- and THC-infused edibles and lifestyle products, together with its recent acquisitions, brings the necessary expertise, access to capital, and infrastructure necessary to create a category leader in cannabis wellness.  

Consumers are flocking to CBD and THC infused products, a market segment that is expected to greatly exceed expenditures for recreational marijuana use. In 2018, just six months after statewide legalization of cannabis for adult use, California consumers spent $1.14 billion on products through 600 licensed cannabis dispensaries. According to Arcview Market Research, the California cannabis industry is predicted to exceed $7.7 billion by 2021– establishing the state as the largest cannabis market in the world.

In addition to the California market GABY has its eyes on the remaining states in the US and on Canada, where its alto™ and Aunt Zelda’s™ products can be sold. According to Cowen & Co., the North American cannabis industry will reach $75 billion by 2030. GABY is positioning itself to participate in this expanded market, and the timing couldn’t be better.

Sophisticated investors are looking beyond the stunning market appreciation of cannabis producers and cultivators to focus on the next wave of cannabis – related startups, namely those industry participants that are downstream of cultivation – manufacturers, distributors and dispensaries.  

GABY may have found the recipe to soar in the multi-billion-dollar THC and CBD based healthy edibles and wellness industry. This market segment is rapidly becoming the growth driver in the cannabis industry as well as the trillion-dollar health and wellness sector.

With significant distribution infrastructure already in place, a proven agility to obtain regulatory clearance, and a tasty portfolio of healthy and therapeutic revenue opportunities, GABY is transitioning into a highly focused, vertically integrated edibles and wellness products company.  

The Strategy Forward

GABY’s successful acquisition of TOP also brought GABY the benefit of Mara Gordon, the founder of TOP who on closing took on the role of Chief Research Officer at GABY. Ms. Gordon brings to GABY her extensive knowledge of the health attributes associated with cannabis and her expertise in formulations. GABY believes that to be the category leader in cannabis wellness it must also be a thought leader. In her role as Chief Research Officer, Ms. Gordon will continue her research into cannabis wellness and education and will continue her work with physicians and clinicians studying cannabis wellness. She will also continue to speak at medical conferences, before policy committees, at industry events and to consumers and retailers to educate, inform and collaborate on the advancement of cannabis wellness.  

GABY is not just well positioned to take advantage of the current market opportunities but is looking beyond the immediate to a time when federal legalization in the US removes the barriers to inter-state commerce. At such time, GABY’s existing infrastructure of major retailers and its distribution networks in both the licensed and unlicensed channels positions the company to rapidly expand into a wide variety of stores across North America with CBD and THC infused products.

Through the first half of 2018 GABY’s revenue rose by 171 percent to approximately $1.2MM, from $450,000 in the first half of 2017. Further growth is expected during the second half of the year following the launch of its alto™ product line as well as from its continuing roll up strategy. TOP’s existing management team projected revenue of US$10 million in 2019, Sonoma is anticipating $7.6 million. With the launch of six cannabis-related products as the foundation of GABY’s continued product development strategy, these unique factors could boost consolidated 2019 annual revenue to ~US$26.7 million (~C$35 million).

Gabriella’s Kitchen (CSE: GABY) has successfully transitioned into one of the only publicly-trading, pure play cannabis edibles and wellness companies listed on the CSE. Investors interested in the intersection between the multibillion-dollar cannabis industry and the trillion-plus dollar wellness industry may want to take a closer look at the company as it gears up to launch additional cannabis infused edibles and wellness products this year while continuing its roll up strategy of acquiring related and complementary companies in this sector.

For more information, visit the company’s website at www.gabriellas-kitchen.com.   

Disclaimer

The above article is sponsored content. Emerging Growth LLC, which owns CannabisFN.com and CFN Media, has been hired to create awareness. Please follow the link below to view our full disclosure outlining our compensation: http://www.cannabisfn.com/legal-disclaimer/

Ryan Allway

About Ryan Allway

Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.

]]> CFN Media’s Exclusive Interview with Pascal Biosciences https://mjshareholders.com/cfn-medias-exclusive-interview-with-pascal-biosciences/ Thu, 08 Nov 2018 14:30:14 +0000 http://www.cannabisfn.com/?p=1866397

Ryan Allway

November 8th, 2018

Exclusive, News, Press Releases, Top Story

The cannabis industry is projected to reach $75 billion by 2030, according to Cowen & Co., driven by the legalization of medical and recreational cannabis across a growing number of states. While many investors are familiar with cultivators and dispensaries, there could be an even greater opportunity on the medical side of the industry. Cannabinoids could displace blockbuster drugs, such as opioids, and provide breakthroughs in other areas.

CFN Media recently sat down with Pascal Biosciences Inc. (TSX-V: PAS) President & CEO Dr. Patrick W. Gray to discuss how the company is harnessing the power of cannabis to develop cancer therapeutics.

CFN Media: Your company hasn’t always been focused on cannabis. What led you to take a closer look at cannabis and discover the molecules that stimulate the immune system to destroy cancer cells?

Dr. Patrick W. Gray: “Our work at Pascal began with our sponsored research at the University of British Columbia. We have a proprietary method to search for compounds that can enhance the immune system, and a cannabinoid had the greatest activity. We have since analyzed nearly 400 cannabinoids–natural, synthetic, and endogenous—and we’ve identified even more potent structures that are currently being tested in preclinical immune-oncology studies. These discoveries about the anti-cancer effects of cannabinoids are novel and fit with Pascal’s goal to develop therapeutics for cancer.”

CFN Media: You recently announced the addition of a new cannabinoid program for the treatment of Glioblastoma. How does this program tie in to your immune surveillance program?

Dr. Patrick W. Gray: “I have known the inventor of this technology, Dr. Nephi Stella, for nearly ten years, and followed his work closely. When I saw his impressive results in a glioblastoma animal model, I was convinced this is a great program for Pascal. Glioblastoma is a terrible form of brain cancer, and I believe Dr. Stella’s cannabinoid-based product has great potential in treating this devastating disease. Furthermore, Dr. Stella will be a consultant for Pascal, and his 20 years of experience with cannabinoids will greatly aid our immune surveillance program. Dr. Stella has done pioneering research with cannabinoids, and he will bring that expertise to our programs.”

CFN Media: Is Pascal considering any partnerships for your cannabinoid programs?

Dr. Patrick W. Gray: “As you mentioned, there is great medical potential for cannabinoids, with a clear benefit for patients with pain, nausea, muscle spasms, epilepsy, and anxiety. However, most clinical studies are suggestive at best, and specific cannabinoids have generally not been associated with patient benefit. Our work is focused on identifying specific cannabinoids with potency for certain ailments. We believe our work will be of significant interest to potential partners, including both cannabis companies and pharmaceutical companies. The value of our programs will continue to increase as we progress, and we intend to engage potential partners when significant value is attained.”

CFN Media: You recently secured a DEA Schedule I license for cannabinoid development. Can you describe the process of securing that license and why it’s significant?

Dr. Patrick W. Gray: “Obtaining a DEA Schedule I license for Research was a critical step in further developing our immune surveillance program using cannabinoids. The process is quite rigorous. Yet, since we received our license, we have screened nearly 400 cannabis derived compounds, many of which are restricted, and have made significant progress in identifying therapeutic candidates.”

CFN Media: What are some of the key upcoming catalysts that shareholders can look forward to? Where do your clinical programs stand at this point in time?

Dr. Patrick W. Gray: “Our cannabinoid-based program for glioblastoma is expected to begin human clinical trials in 2019, a significant milestone for the company. In addition, our immune surveillance program is progressing nicely with some exciting discoveries. We will report our advancements in the scientific literature, at international conferences, and in press releases. Investors can expect updates on our programs in a timely fashion, because we have a lot of exciting information to share!”

CFN Media: Why should investors consider your stock?

Dr. Patrick W. Gray: “Pascal has an exciting pipeline developing cannabinoid therapeutics for cancer. Cannabinoid-based medicines are a fast-growing opportunity given the legalization of cannabis in Canada. The current competitive landscape for biotechnology companies developing cannabinoid therapeutics is small with diverse indications. Pascal stands out as one of the few companies targeting glioblastoma and, more broadly, cancer in combination with checkpoint inhibitors. Our utmost priority is to help patients suffering from life-threatening diseases, and we strongly believe that our current portfolio can make an impact on patient lives.”

CFN Media: Thank you for taking the time to speak with us.

About Pascal Biosciences Inc.

Pascal Biosciences Inc. (TSX-V:PAS) is a biotechnology company focused on advancing innovative approaches for the treatment of cancer including cannabinoid-based therapeutics and targeted therapies. The company’s leading cannabinoid portfolio comprises a small molecule therapeutic, ST-403, that is advancing into clinical trials for the treatment of glioblastoma, and an immuno-stimulatory molecule. In addition, Pascal Biosciences is developing a B-cell targeted antibody for acute lymphoblastic leukemia and an antibody for calcium channels expressed by the immune system. For more information, visit www.pascalbiosciences.com.

To learn more, visit: https://www.pascalbiosciences.com/.

Disclaimer

The above article is sponsored content. Emerging Growth LLC, which owns CannabisFN.com and CFN Media, has been hired to create awareness. Please follow the link below to view our full disclosure outlining our compensation: http://www.cannabisfn.com/legal-disclaimer/

Ryan Allway

About Ryan Allway

Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.

]]>